LY96 and influenza: Therapeutic administration of an LPS analog antagonist, Eritoran (E5564) (21, 22) that acts by competing for the LPS-binding site on MD-2 (23), resulted in a dose- and time-dependent protection of mice from lethal influenza infection when administered starting on day 2 post-infection once daily for 5 consecutive days (24).